Welcome to our dedicated page for MYRIAD GENETICS SEC filings (Ticker: MYGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Myriad Genetics Inc. filings document the regulatory record of a molecular diagnostics and precision medicine company. Recent Form 8-K reports furnish quarterly and annual financial results, preliminary revenue and test-volume information, guidance, and product-related operating updates tied to Cancer Care Continuum, Prenatal Health, Mental Health, Precise MRD, and MyChoice CDx.
The company's proxy materials cover board matters, executive compensation, equity awards, and annual meeting governance. Other current reports document officer transitions, compensatory arrangements, and amendments to previously furnished earnings materials, providing formal disclosure of governance changes and financial-reporting corrections.